Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Intellia Therapeutics announced that the FDA has accepted its Biologics License Application (BLA) for lonvoguran ziclumeran (lonvo-z), the world's first in vivo CRISPR-based therapy and a potential one-time treatment for hereditary angioedema (HAE). The FDA has granted Priority Review with a PDUFA date of March 10, 2027, signaling a potentially exp…